SoftBank Vision Fund-backed immunology therapy developer Vir will float at the bottom of its range, having raised in excess of $820m in VC funding in roughly three years.

Vir Biotechnology, a US-based immunology drug developer backed by telecommunications group SoftBank, will float today in a $143m initial public offering on the Nasdaq Global Select Market. The company priced approximately 7.14 million shares on the low end of the IPO’s $20 to $22 range, valuing it at about $2.19bn. Joint book-running managers Goldman Sachs,…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.